The History of Erythromycin

The Discovery: 1949–1952

The story of erythromycin begins in the Philippines. Abelardo Aguilar, a physician working for Eli Lilly as a medical representative, collected soil samples in Iloilo in 1949 and screened them for antibacterial organisms — the same soil-screening approach that had produced streptomycin and the tetracyclines in the 1940s.

From these samples, the researcher isolated a strain of actinomycete bacteria initially designated as Streptomyces erythreus (later reclassified as Saccharopolyspora erythraea). The organism produced a compound with potent antibacterial activity against gram-positive bacteria. Aguilar sent the samples to Lilly's research laboratories in Indianapolis in 1949, where McGuire and colleagues spent three years characterizing and developing the compound; their report appeared in Antibiotics & Chemotherapy in 1952.

Early Development Challenges

Pharmaceutical scientists faced significant challenges in developing erythromycin for clinical use. The compound was unstable in acidic conditions, making oral formulation difficult. It also exhibited poor water solubility, complicating intravenous preparation. The team worked to optimize fermentation conditions, achieving higher yields through medium optimization and strain improvement.

By 1952, production had been successfully scaled and Lilly launched erythromycin as Ilotycin; the later estolate product, Ilosone, is widely reported to be named after Iloilo, where the organism was found. Aguilar did not receive royalties for the discovery and later sought compensation from Lilly without success.

Commercial Development: 1952–1960s

Erythromycin entered the market at a critical time in antibiotic history. Penicillin resistance was emerging, and physicians needed alternatives for penicillin-allergic patients. The new macrolide filled this gap perfectly, offering broad-spectrum coverage with a novel mechanism of action.

Patent Competition

The early commercial period saw intense patent disputes. While the original manufacturer held the initial patents, other pharmaceutical companies developed their own erythromycin products using different manufacturing processes. This competition drove innovation in formulation development and helped reduce costs through market competition.

Global Expansion

By the late 1950s, erythromycin production had expanded globally:

• Major pharmaceutical companies scaled production in North America
• Pharmaceutical companies in Europe began licensed production
• Japan's pharmaceutical industry adopted erythromycin manufacturing
• Generic production began as initial patents expired

Annual production reached hundreds of tons by 1960, making erythromycin one of the world's most prescribed antibiotics. Its inclusion in the WHO Model List of Essential Medicines in 1977 confirmed its global importance.

Development of Ester Salts: 1960s–1970s

The inherent instability of erythromycin base in gastric acid led to erratic oral absorption and gastrointestinal side effects. Pharmaceutical companies developed various ester and salt formulations to address these limitations:

Erythromycin Stearate (1954)

The stearate salt improved stability in tablet formulations but still required protection from gastric acid. Manufacturers developed enteric-coated tablets that released the drug in the small intestine, improving bioavailability from 18% to approximately 30%.

Erythromycin Ethylsuccinate (1956)

This ester prodrug offered better stability in liquid formulations, making it ideal for pediatric suspensions. The ethylsuccinate ester is absorbed intact and hydrolyzed to active erythromycin in the blood and tissues. Its pleasant taste and stability made it the preferred pediatric formulation.

Erythromycin Estolate (1959)

The lauryl sulfate salt of the propionyl ester provided the best oral bioavailability (up to 50%) and most consistent absorption. However, it was associated with increased risk of cholestatic hepatitis, particularly with repeated courses, leading to restricted use in many countries.

Erythromycin Lactobionate (1952)

Developed for intravenous administration, this water-soluble salt enabled treatment of severe infections. The lactobionate formulation remains the standard for parenteral erythromycin, though it requires careful dilution and slow infusion to prevent thrombophlebitis.

Second-Generation Macrolides: 1980s–1990s

Despite formulation improvements, erythromycin's limitations — frequent dosing, gastrointestinal intolerance, and drug interactions — drove development of semi-synthetic derivatives:

Clarithromycin (1991)

Scientists at Taisho Pharmaceutical in Japan developed 6-O-methylerythromycin (clarithromycin) in the early 1980s. It was approved in Japan and, as Biaxin (Abbott), in the United States in 1991. The methylation at position 6 prevented degradation by gastric acid, improving oral bioavailability to 55% and reducing GI side effects.

Key advantages over erythromycin:

• Twice-daily dosing (vs 3–4 times daily)
• Better tissue penetration
• Enhanced activity against Haemophilus influenzae and atypical mycobacteria
• 14-OH metabolite retains antibacterial activity
• Fewer gastrointestinal side effects

Azithromycin (discovered 1980; US approval 1991)

Scientists at Pliva in Zagreb (then Yugoslavia, now Croatia) created azithromycin in 1980 by inserting a nitrogen atom into the erythromycin lactone ring, creating the first azalide antibiotic. Pliva launched it in Central and Eastern Europe as Sumamed in 1988, and Pfizer, under license, gained US FDA approval for Zithromax in 1991.

Breakthrough features:

• 68-hour half-life enabling once-daily dosing
• 3-day and 5-day treatment regimens (Z-Pak)
• Extensive tissue distribution (tissue:plasma ratio >50:1)
• Minimal CYP3A4 interaction
• Superior H. influenzae coverage
• Single-dose treatment for chlamydial urethritis

Azithromycin became one of the most prescribed antibiotics globally, with the convenient Z-Pak formulation driving widespread adoption. However, this popularity contributed to resistance development.

Roxithromycin (1987)

Roxithromycin featured an N-oxime side chain improving acid stability. While popular in Europe and Asia, it never received FDA approval for the United States market. It offers once or twice-daily dosing with fewer drug interactions than erythromycin.

Modern Era: 2000–Present

Third-Generation Development

Rising macrolide resistance prompted development of ketolides — semi-synthetic derivatives designed to overcome common resistance mechanisms:

Telithromycin (2004): The first ketolide approved for clinical use (Ketek), featuring a 3-keto group replacing the L-cladinose sugar. Initially promising for respiratory infections, it was restricted due to severe hepatotoxicity reports.

Solithromycin: A fluoroketolide in development, showing activity against macrolide-resistant pneumococci. Clinical trials for community-acquired pneumonia showed promise, but FDA approval was not granted due to safety concerns.

Current Research Directions

Modern erythromycin research focuses on:

• Non-antibiotic applications: Exploiting motilin receptor agonism for gastrointestinal motility disorders
• Anti-inflammatory properties: Investigating immunomodulatory effects in chronic lung diseases
• Resistance reversal: Developing inhibitors of efflux pumps and methyltransferases
• Hybrid antibiotics: Combining macrolide scaffolds with other antibiotic classes

Legacy and Impact

Erythromycin's discovery marked several important milestones in pharmaceutical history:

Scientific Impact

• First commercially successful macrolide antibiotic
• Validated soil screening as a source for novel antibiotics
• Established the 50S ribosomal subunit as an antibacterial target
• Template for semi-synthetic antibiotic development

Clinical Impact

• Provided crucial alternative for penicillin-allergic patients
• Enabled treatment of atypical respiratory pathogens
• Standard prophylaxis for neonatal eye infections
• Treatment option for pertussis, diphtheria, and Legionnaires' disease

Global Health Impact

Erythromycin has saved millions of lives over seven decades. Its inclusion on the WHO Essential Medicines List ensures availability in resource-limited settings. The drug remains important for neonatal eye prophylaxis, infant chlamydial infections, pertussis outbreaks, and rheumatic fever prophylaxis in penicillin-allergic patients.

Recognition of the Discovery

For decades, popular accounts credited erythromycin solely to Eli Lilly. Abelardo Aguilar never received financial compensation, and his story is now frequently cited in discussions of fair benefit-sharing for discoveries made with biological material from developing countries. Recent historical accounts give him explicit credit as the discoverer of the producing organism.

Key Timeline

Related Topics